Truist Securities models $730M peak revenue for Protagonist Therapeutics (PTGX) in Icotyde royalties
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| (NASDAQ: PTGX) | Delayed: 143.37 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $143.37 | 52 Week High | $24.52 | |||
| Open | $143.37 | 52 Week Low | $10.02 | |||
| Day High | $143.37 | P/E | N/A | |||
| Day Low | $143.37 | EPS | $0.00 | |||
| Volume | 756 | |||||
